Table 1.
The summary of the results of various immunological tests both at the first visit 4 years before and at the time of relapse after the COVID-19 vaccination.
| First visit (16 year old ) | Relapse (20 year old) | |
|---|---|---|
| DIF (BMZ) IgG | (+) | (+) |
| DIF (BMZ) IgA | (–) | (–) |
| DIF (BMZ) IgM | (+) | (+) |
| DIF (BMZ) C3c | (+) | (+) |
| IIF (BMZ) IgG | (+) × 40 | (–) |
| IIF (BMZ) IgM | (–) | (–) |
| ss-IIF (epidermis) IgG | (–) | (–) |
| ss-IIF (epidermis) IgM | (+) × 10 | (+) × 40 |
| ss-IIF (dermis) IgG | (+) × 40 | (+) × 40 |
| ss-IIF (dermis) IgM | (–) | (–) |
| IgG Dermal extract IB: 290 kDa | Pos | Neg |
| IgG Dermal extract IB: 200 kDa | Neg | Neg |
| IgG Dermal extract IB: laminin 332 | Neg | Neg |
| IgG ELISAs type VII collagen (cut-off Index < 6.14) | 39.76 | 5.78 |
| Anti-BP180 NC16A IgG ELISA | Neg | Neg |
| Anti-BP230 IgG ELISA | Neg | Neg |
BMZ, basement membrane zone; DIF, direct immunofluorescence; IB, immunoblotting; IIF, indirect immunofluorescence; Neg, negative; Pos; positive; ss-IIF, 1M NaCl split skin indirect immunofluorescence; (+), linear deposits of immunoreactants; (–), no deposits of immunoreactants.